Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney

被引:164
作者
Ito, Sumito [1 ]
Kusuhara, Hiroyuki [1 ]
Yokochi, Miyu [1 ]
Toyoshima, Junko [1 ]
Inoue, Katsuhisa [2 ]
Yuasa, Hiroaki [2 ]
Sugiyama, Yuichi [1 ]
机构
[1] Univ Tokyo, Lab Mol Pharmacokinet, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Nagoya City Univ, Dept Biopharmaceut, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi, Japan
基金
日本学术振兴会;
关键词
RENAL TUBULAR SECRETION; IN-VIVO; FUNCTIONAL-CHARACTERIZATION; METFORMIN; HUMANS; PROCAINAMIDE; RANITIDINE; CLEARANCE; ELIMINATION; MEMBRANE;
D O I
10.1124/jpet.111.184986
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cimetidine, an H 2 receptor antagonist, has been used to investigate the tubular secretion of organic cations in human kidney. We report a systematic comprehensive analysis of the inhibition potency of cimetidine for the influx and efflux transporters of organic cations [human organic cation transporter 1 (hOCT1) and hOCT2 and human multidrug and toxin extrusion 1 (hMATE1) and hMATE2-K, respectively]. Inhibition constants (K-i) of cimetidine were determined by using five substrates [tetraethylammonium (TEA), metformin, 1-methyl-4-phenylpyridinium, 4-(4-(dimethylamino) styryl)-N-methylpyridinium, and m-iodobenzylguanidine]. They were 95 to 146 mu M for hOCT2, providing at most 10% inhibition based on its clinically reported plasma unbound concentrations (3.6 -7.8 mu M). In contrast, cimetidine is a potent inhibitor of MATE1 and MATE2-K with K-i values (mu M) of 1.1 to 3.8 and 2.1 to 6.9, respectively. The same tendency was observed for mouse Oct1 (mOct1), mOct2, and mouse Mate1. Cimetidine showed a negligible effect on the uptake of metformin by mouse kidney slices at 20 mu M. Cimetidine was administered to mice by a constant infusion to achieve a plasma unbound concentration of 21.6 mu M to examine its effect on the renal disposition of Mate1 probes (metformin, TEA, and cephalexin) in vivo. The kidney-and liver-toplasma ratios of metformin both were increased 2.4-fold by cimetidine, whereas the renal clearance was not changed. Cimetidine also increased the kidney-to-plasma ratio of TEA and cephalexin 8.0-and 3.3-fold compared with a control and decreased the renal clearance from 49 to 23 and 11 to 6.6 ml/ min/ kg, respectively. These results suggest that the inhibition of MATEs, but not OCT2, is a likely mechanism underlying the drug-drug interactions with cimetidine in renal elimination.
引用
收藏
页码:393 / 403
页数:11
相关论文
共 43 条
[1]   Effcet of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide [J].
Abel, S ;
Nichols, DJ ;
Brearley, CJ ;
Eve, MD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (01) :64-71
[2]  
BENDAYAN R, 1990, EUR J CLIN PHARMACOL, V38, P165
[3]   Characterization of regulatory mechanisms and states of human organic cation transporter [J].
Biermann, J ;
Lang, D ;
Gorboulev, V ;
Koepsell, H ;
Sindic, A ;
Schröter, R ;
Zvirbliene, A ;
Pavenstädt, H ;
Schlatter, E ;
Ciarimboli, G .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2006, 290 (06) :C1521-C1531
[4]  
BLAKE GM, 1989, EUR J NUCL MED, V15, P618
[5]   Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine [J].
Busch, AE ;
Karbach, U ;
Miska, D ;
Gorboulev, V ;
Akhoundova, A ;
Volk, C ;
Arndt, P ;
Ulzheimer, JC ;
Sonders, MS ;
Baumann, C ;
Waldegger, S ;
Lang, F ;
Koepsell, H .
MOLECULAR PHARMACOLOGY, 1998, 54 (02) :342-352
[6]   CIMETIDINE INHIBITS RENAL PROCAINAMIDE CLEARANCE [J].
CHRISTIAN, CD ;
MEREDITH, CG ;
SPEEG, KV .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (02) :221-227
[7]   The organic cation transporter OCT2 mediates the uptake of β-adrenoceptor antagonists across the apical membrane of renal LLC-PK1 cell monolayers [J].
Dudley, AJ ;
Bleasby, K ;
Brown, CDA .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (01) :71-79
[8]   Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation:: An in vitro-in vivo study [J].
Feng, B. ;
Obach, R. S. ;
Burstein, A. H. ;
Clark, D. J. ;
de Morais, S. M. ;
Faessel, H. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (04) :567-576
[9]   The clinical pharmacokinetics of levofloxacin [J].
Fish, DN ;
Chow, AT .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :101-119
[10]  
FLETCHER CV, 1995, PHARMACOTHERAPY, V15, P701